|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
August 16, 2005MS: Biogen Licenses New MS Drug
Click to read...The deal includes codevelopment rights for Daclizumab, an antibody that has shown promise in preventing transplanted organ rejection and in treating asthma and multiple sclerosis. Positive news about Daclizumab trials underway could bolster Biogen Idec's multiple sclerosis franchise, which has faltered this year since the voluntary suspension of Tysabri, an MS treatment that resulted in unexpected illnesses in several patients who used it during clinical trials.
|